



A Sensitive and Robust Immunocapture LC-MS/MS Workflow for Quantitation of Infliximab in Human Plasma

Increasing sensitivity for better accuracy, robustness, and LLOQ when quantitating Infliximab in complex biological samples

SCIEX iMethodTM Applications for Pharma and BioPharma

Key Challenges of Infliximab Quantitation Using ELISA Assay

- **Substandard data quality** Precision and accuracy are compromised at low levels due to interferences.
- Limited linear dynamic range and hook effect –Hook effect is known limitation for ELISA assay which causes false negative or artificial lower results. Only up to three orders of dynamic range for most ELISA assay.
- Limitations on multiplexing assay (MPX): -MPX assay involves potential interactions between multiple different antibodies and antigens in the sample/assay solution.

Key Benefits of the BioBA Solution for Quantifying Infliximab

- Sample preparation Increased efficiency with included reagent kit, sample preparation SOP, and LC-MS/MS detail method
- Mass spec selectivity: Quantitation infliximab antibody using unique peptide sequence with highly reproducibile and accurate quality data even at low end.
- Easy to multiplexing on Mass spec: By simply adding other biological compound unique peptide MRM transitions, the method can monitor large number of biological analytes in one injection without concerning interferences and compromise data quality.
- Maximized sensitivity QTRAP® 6500 LC-MS/MS Increased ionization efficiency and heat transfer with the new IonDrive™ Turbo V source and Increased ion sampling efficiency and ruggedness with the new IonDrive QJet™ ion guide results in LOQ of 5 ng/ML
- Large linear dynamic range Measurements tested from 5–50,000 ng/mL are linear with 5-orders of magnitude (r = 0.99943).
- Wide mass range range of m/z 5 2000 provides versatility for large peptide quantitation

Results and Discussion

Sensitivity and linearity of quantitation

A calibration curve of infliximab standards in human whole plasma matrix (5 – 50,000 ng/mL) was generated using MultiQuantTM Software (Figure 1). The tested limit of quantification (LOQ) was 5 ng/mL in plasma. Linearity was achieved from 5-50,000 ng/mL with regression coefficient (r) of 0.99943.





Figure 1: Linear response for Infliximab peptide in human plasma. Calibration range: 5 ng/mL - 50 µg/mL



Figure 2: Chromatograms spiked Infliximab in human plasma: blank plasma, 5, 50, and 500 ng/mL



Table 1: Quantitation Statistics of Infliximab in Human Plasma Using Conventional HPLC System

Component Name	Actual Concentration	Num, Values	Mean	Standard Deviation	Percent CV	Accuracy	Value #1	Value #2	Value #3
YASESMSGIPSR.+2y10 LC	5.00	3 of 3	5.81	0.49	8.43	116.27	5.95	6.22	5.27
YASESMSGIPSR +2y10 LC	10.00	3 of 3	10.50	0.15	1.44	104.95	10.37	10.66	10.46
YASESMSGIPSR +2y10 LC	50.00	3 ef 3	46.80	3.30	7.06	93.60	50.32	46.32	43.76
YASESMSGIPSR+2y10LC	100.00	3 of 3	99.91	7.43	7.43	99.91	107.46	99.64	92.62
YASESMSGIPSR.+2y10 LC	500.00	3 of 3	445.13	7.58	1.70	89.03	451.34	447.37	436.68
YASESMOGIPSR.+2y10 LC	1000.00	3 of 3	1016.93	41.30	4.06	101.69	1063.03	983.32	1004.44
YASESMSGIPSR +2y10 LC	5000.00	3 of 3	4656.39	385.98	8.29	93.13	5080.43	4325.52	4563.22
YASESMSGIPSR +2y10 LC	10000.00	3 of 3	10081.91	392.72	3.90	100.82	10332.51	10283.92	9629.31
YASESMSGIPSR+2y10LC	50000.00	3 of 3	50301.62	891.58	1.77	100.60	50322.63	51182.51	49399 72

Conclusion

- The SCIEX Triple Quad[™] LC-MS/MS and QTRAP 6500 systems with IonDrive technology provide high sensitivity to perform high throughput peptide quantitation
- The peptide properties, stability, and non-specific adsorption for insulin infliximab were considered as part of the method development process, resulting in a robust quantitative assay
- Infliximab levels were robustly quantified at 5ng/mL with less than 10% CV in human plasma using a conventional high flow LC methodology. The linear dynamic range was 5– 50,000ng/mL. The quantitation limit and calibration range can be adjusted based on specific assay requirements.

For Research Use Only. Not for use in diagnostic procedures. © 2015 AB Sciex. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX[™] is being used under license.

RUO-MKT-02-2251-A

